sr141716 has been researched along with Metabolic Diseases in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Chorvat, RJ | 1 |
| Abell, L; Ahmad, S; Apedo, A; Azzara, AV; Brigance, R; Chang, S; Chao, H; Chen, L; Cheng, D; Chu, CH; Cullen, MJ; Dabros, M; Devasthale, P; Dierks, E; Foster, K; Gao, Q; Hangeland, JJ; Harden, D; Harvey, S; Hou, X; Keim, WJ; Kempson, J; Kopcho, L; Lawrence, RM; Li, YX; Ma, Z; Mathur, A; Meng, W; Moore, F; O'Malley, K; Panemangelor, R; Pelleymounter, MA; Robl, JA; Rooney, S; Turdi, H; Wang, W; Whaley, JM; Wu, DR; Ye, XY; Zhao, G | 1 |
| Davidova, A; Hambly, C; Hundal, HS; Irving, AJ; Lipina, C; Mitchell, SE; Speakman, JR; Storey-Gordon, E; Vaanholt, LM | 1 |
| Carlson, OD; Cieśla, Ł; Cimbro, R; Doyle, ME; Egan, JM; Ghosh, S; González-Mariscal, I; Krzysik-Walker, SM; Liu, QR; Moaddel, R; O'Connell, JF; Santa-Cruz Calvo, S; Witek, RP | 1 |
| Kapoor, S | 1 |
| Pacher, P | 1 |
| Paquot, N; Scheen, AJ | 1 |
| Crippa, JA; Moreira, FA | 1 |
| Aguirre, CA; Castillo, VA; Llanos, MN; Ronco, AM; Valenzuela, CA | 1 |
| Di Marzo, V; Silvestri, C | 1 |
| Després, JP; McCarthy, C; Pi-Sunyer, X; Scheen, A; Van Gaal, L | 1 |
4 review(s) available for sr141716 and Metabolic Diseases
| Article | Year |
|---|---|
Peripherally restricted CB1 receptor blockers.
Topics: Animals; Brain; Cocaine; Drug Discovery; Humans; Liver Diseases; Metabolic Diseases; Morpholines; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Sulfonamides | 2013 |
Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders.
Topics: Atherosclerosis; Blood Glucose; Cannabinoid Receptor Modulators; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Fasting; Glucose; Glycated Hemoglobin; Humans; Lipid Metabolism; Metabolic Diseases; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors | 2009 |
The psychiatric side-effects of rimonabant.
Topics: Anxiety Disorders; Appetite Depressants; Cannabinoid Receptor Modulators; Depressive Disorder; Humans; Metabolic Diseases; Obesity; Piperidines; Placebo Effect; Pyrazoles; Randomized Controlled Trials as Topic; Receptor, Cannabinoid, CB1; Rimonabant; Smoking; Smoking Cessation | 2009 |
Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders.
Topics: Animals; Cannabinoid Receptor Antagonists; Drug Design; Drug Inverse Agonism; Endocannabinoids; Humans; Metabolic Diseases; Obesity, Abdominal; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors | 2012 |
7 other study(ies) available for sr141716 and Metabolic Diseases
| Article | Year |
|---|---|
Screening Hit to Clinical Candidate: Discovery of BMS-963272, a Potent, Selective MGAT2 Inhibitor for the Treatment of Metabolic Disorders.
Topics: Animals; Crystallography, X-Ray; Drug Discovery; Enzyme Inhibitors; High-Throughput Screening Assays; Humans; Metabolic Diseases; N-Acetylglucosaminyltransferases; Structure-Activity Relationship | 2021 |
CB1 receptor blockade counters age-induced insulin resistance and metabolic dysfunction.
Topics: Age Factors; Animals; Cannabinoid Receptor Antagonists; Cell Line; Eating; Energy Metabolism; Gene Expression; Insulin Resistance; Male; Metabolic Diseases; Mice; Mice, Inbred C57BL; Piperidines; Pyrazoles; Rats; Receptor, Cannabinoid, CB1; Rimonabant | 2016 |
Human CB1 Receptor Isoforms, present in Hepatocytes and β-cells, are Involved in Regulating Metabolism.
Topics: Amino Acid Sequence; Animals; Cells, Cultured; CHO Cells; Cricetinae; Cricetulus; Gene Expression Profiling; Glucose; Hepatocytes; Humans; Insulin; Insulin Secretion; Insulin-Secreting Cells; Metabolic Diseases; Piperidines; Protein Isoforms; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Sequence Homology, Amino Acid; Sulfonamides | 2016 |
Rimonabant: a rapidly expanding role in the management of metabolic and systemic disorders besides polycystic ovarian syndrome.
Topics: Cannabinoid Receptor Antagonists; Depression; Female; Humans; Metabolic Diseases; Piperidines; Polycystic Ovary Syndrome; Pyrazoles; Rimonabant | 2009 |
Cannabinoid CB1 receptor antagonists for atherosclerosis and cardiometabolic disorders: new hopes, old concerns?
Topics: Animals; Atherosclerosis; Cannabinoids; Clinical Trials as Topic; Heart Diseases; Humans; Metabolic Diseases; Mice; Mice, Knockout; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptors, LDL; Rimonabant; Weight Gain | 2009 |
The CB₁ receptor antagonist SR141716A reverses adult male mice overweight and metabolic alterations induced by early stress.
Topics: Adipose Tissue; Animals; Animals, Newborn; Body Weight; Drug Evaluation, Preclinical; Epididymis; Female; Hormones; Male; Metabolic Diseases; Mice; Overweight; Piperidines; Pregnancy; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Stress, Psychological; Time Factors | 2011 |
Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.
Topics: Cannabinoid Receptor Antagonists; Cannabinoids; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Diet, Reducing; Exercise; Heart Diseases; Humans; Metabolic Diseases; Obesity; Overweight; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Safety | 2008 |